PPARA and Parkinson disease: However, a double-blinded placebo controlled clinical trial testing pioglitazone, also a PPAR agonist, failed to modify progression in PD patients and the investigators did not recommend a larger trial (NINDS Exploratory Trials in Parkinson’s Disease (NET-PD) ZONE Investigators, 2015).